{
    "nctId": "NCT02472353",
    "briefTitle": "Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer",
    "officialTitle": "A Phase II Pilot Study Using Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Breast Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Number of Participants With Less Than or Equal to 5% Decrease in Left Ventricle Ejection Fraction (LVEF) on Echocardiogram",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer requiring neoadjuvant or adjuvant therapy with doxorubicin\n* Complete metabolic panel demonstrating adequate organ functions as defined by the following: Aspartate transaminase (AST) less than 2.5 times Upper Limit of Normal (ULN); Alanine transaminase (ALT) less than 2.5 times ULN; alkaline phosphatase less than 2.5 times ULN; serum creatinine less than 1.5 mg/dL; serum bilirubin less than ULN\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Age greater than or equal to 21 years\n\nExclusion Criteria:\n\n* Known diabetes\n* History of cardiac arrhythmias or symptomatic cardiac disease\n* Currently taking antiarrhythmic medications, beta-blockers, or other rate controlling cardiac medications\n* Currently taking metformin and/or sulfonylureas\n* Known hypersensitivity or intolerance to metformin\n* Baseline ejection fraction of less than 50% measured by echocardiogram\n* Known hypersensitivity to contrast used during echocardiogram\n* Risk factors associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heard failure, history of acidosis, habitual intake of 3 or more alcoholic beverages per day)\n* Pregnant or breast feeding",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}